Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.50 |
| ▸ | IDH1 | O75874 | 4/20 | 0.49 |
| ▸ | VDR | P11473 | 5/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 5/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5069788 | 0.92 | RPS6KB1 (0.52) | RPS6KB1IDH1VDRNR1H4L3MBTL1 | |
| SCHEMBL5066585 | 0.91 | NR1H4 (0.54) | IDH1VDRNR1H4L3MBTL1 | |
| SCHEMBL5517542 | 0.84 | SIRT2 (0.55) | RPS6KB1IDH1VDRNR1H4L3MBTL1 | |
| SCHEMBL12150498 | 0.84 | L3MBTL1 (0.50) | IDH1VDRNR1H4L3MBTL1MAPT | |
| SCHEMBL5511355 | 0.83 | L3MBTL1 (0.57) | IDH1VDRNR1H4L3MBTL1MAPT | |
| SCHEMBL791364 | 0.83 | L3MBTL1 (0.57) | IDH1VDRNR1H4L3MBTL1MAPT | |
| SCHEMBL5065691 | 0.83 | RPS6KB1 (0.61) | RPS6KB1IDH1L3MBTL1NPSR1PTGER4 | |
| SCHEMBL5519080 | 0.83 | MAOB (0.49) | IDH1VDRNR1H4L3MBTL1MAPT | |
| SCHEMBL5514164 | 0.82 | L3MBTL1 (0.52) | IDH1VDRNR1H4L3MBTL1MAPT | |
| SCHEMBL5518839 | 0.82 | L3MBTL1 (0.55) | IDH1VDRNR1H4L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080247992-A1 | NITROGEN-CONTAINING HETEROARYL DERIVATIVES | GENELABS TECHNOLOGIES, INC. | 2008-10-09 | — | — | US | disclosed |
| US-20080247992-A1 | NITROGEN-CONTAINING HETEROARYL DERIVATIVES | GENELABS TECHNOLOGIES, INC. | 2008-10-09 | — | — | US | disclosed |
| US-20080247992-A1 | NITROGEN-CONTAINING HETEROARYL DERIVATIVES | GENELABS TECHNOLOGIES, INC. | 2008-10-09 | — | — | US | disclosed |
| US-7304085-B2 | Nitrogen-containing heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304085-B2 | Nitrogen-containing heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304085-B2 | Nitrogen-containing heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| US-20050154040-A1 | Nitrogen-containing heteroaryl derivatives | SMITHKLINE BEECHAM CORPORATION | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080247992-A1 | NITROGEN-CONTAINING HETEROARYL DERIVATIVES | EIF2AK2, MAVS, NSUN3 | RPS6KB1 3476/4885IDH1 156/4885VDR 3893/4885 |
| US-20050154040-A1 | Nitrogen-containing heteroaryl derivatives | EIF2AK2, MAVS, NSUN3 | RPS6KB1 3476/4885IDH1 156/4885VDR 3893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.